전이성 방광이행상피세포암에 대한 M-VAC(Methotrexate, Vinblastine, Doxorubicin and Cisplatin)
M-VAC(Methotrexate, Viblatine, Doxorubicine and Cisplatinum) Chemotherapy forMetastatic Transitional Cell Carcinoma
전일선, 이병진, 손신영,
소속 상세정보
전일선 ( )
경희대학교
이병진 ( )
경희대학교
손신영 ( )
경희대학교
KMID : 0358319950360050502
Abstract
We treated 23 patients with metastatic transitional cell carcinoma with methotrexate, vinblastine, doxorubicin and cisplatinum (M-VAC) chemotherapy from March 1989 to June 1994.
The mean age of the patients was 60.0 years old and ranged from 49 years olf to 75 years old. They were 18 in male and 5 in female.
Complete clinical remission was observed in 5 of 23 patients (21.7%) and 6 patients (26.1%) ahd a partial remission. An overall objective response rate was 47.8%.
The median survival was 12.4 months in all 23 patients, and 20.6+ months in 5 complete responder, 8.9 months in non-responder. The duration of survival of the patients with complete remission was prolonged significantly compared to the patients
with
progression.
The progression of disease was in 3 of 4 patients with metastatic bone lesion in effect of M-VAC chemotherapy, but complete clinical remission was 1 of 4 patients.
After treatment, complete clinical remission was observed in 5 of 18 patients with metastatic lymph node and 5 patients had a partial remission. The progression of disease was in 1 patient with lung and liver metastatic lesions.
Toxicity included moderate to severe myelosuppression that resulted in sepassis in 3 patients and mild to moderately anorexia, vomiting, alopecia and reanl dysfunction.
It was suggested that M-VAC chemotheraphy may be effective as treatment for patients with metastatic transitional cell carcinoma.
키워드
원문 및 링크아웃 정보
등재저널 정보